
Plasma Therapy Market Report 2026
Global Outlook – By Type (Pure PRP, Leukocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), By Application (Orthopedics, Arthritis, Chronic Tendinitis, Bone Repair & Regeneration, Dermatology, Androgenic Alopecia, Plastic Surgery, Dental, Cardiac Muscle Injury, Other Applications), By End-Users (Hospitals & Clinics, Laboratories (Research Institutes) – Market Size, Trends, Strategies, and Forecast to 2035
Plasma Therapy Market Overview
• Plasma Therapy market size has reached to $0.61 billion in 2025 • Expected to grow to $1.13 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Increasing Osteoarthritis Cases Boost Demand Of Plasma Therapy Market • Market Trend: New Product Launches To Address Cater Evolving Treatment Needs • North America was the largest region in 2025 and Middle East is the fastest growing region.What Is Covered Under Plasma Therapy Market?
Plasma therapy refers to a treatment that substitutes missing or inadequate proteins to help people live healthier and more fruitful lives. It introduces antibodies into individuals receiving therapy using blood donated by recovered patients. The main types of plasma therapy are pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). Pure Platelet-Rich Plasma (P-PRP) or leucocyte-poor PRP goods are activated preparations that lack leucocytes and have a low-density fibrin system. The different applications include orthopedics, arthritis, chronic tendinitis, bone repair and regeneration, dermatology, androgenic alopecia, plastic surgery, dental, cardiac muscle injury, and others, and are implemented in various sectors such as hospitals and clinics, laboratories, and research institutes.
What Is The Plasma Therapy Market Size and Share 2026?
The plasma therapy market size has grown rapidly in recent years. It will grow from $0.61 billion in 2025 to $0.69 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited awareness about plasma therapy benefits, reliance on conventional treatments, growing orthopedic and sports medicine procedures, increasing hospital and clinic infrastructure, early adoption of prp in cosmetic procedures.What Is The Plasma Therapy Market Growth Forecast?
The plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $1.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of advanced prp and prf formulations, rising regenerative medicine research, expansion of plasma therapy applications in chronic and cardiac injuries, increasing adoption in dermatology and dental care, growth of clinical trials and research institutes. Major trends in the forecast period include growing adoption of platelet-rich plasma (prp) and platelet-rich fibrin (prf) therapies, expansion of regenerative medicine and orthopedic applications, increasing use in dermatology, hair restoration, and plastic surgery, rising demand for injectable and membrane-based fibrin products, integration of research and clinical trials for enhanced therapeutic outcomes.Global Plasma Therapy Market Segmentation
1) By Type: Pure PRP, Leukocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF) 2) By Application: Orthopedics, Arthritis, Chronic Tendinitis, Bone Repair & Regeneration, Dermatology, Androgenic Alopecia, Plastic Surgery, Dental, Cardiac Muscle Injury, Other Applications 3) By End-Users: Hospitals & Clinics, Laboratories: Research Institutes Subsegments: 1) By Pure PRP: High Concentration PRP, Low Concentration PRP 2) By Leukocyte-Rich PRP: PRP With White Blood Cells, PRP With Growth Factors 3) By Pure Platelet-rich Fibrin (PRF): Injectable PRF, Membrane PRF 4) By Leukocyte-rich Fibrin (L-PRF): L-PRF Clots, L-PRF MembranesWhat Is The Driver Of The Plasma Therapy Market?
The rising cases of osteoarthritis are expected to drive the plasma therapy market during the forecast period. Platelet-rich plasma (PRP), a type of plasma therapy, is considered a safe and efficient treatment for osteoarthritis. Platelet-rich plasma (PRP) is a concentrated autologous blood growth factor that is injected into the joint to provide symptomatic relief by decreasing inflammation and slowing the progression of osteoarthritis. For instance, in September 2023, according to the Journal of Elsevier, a Netherlands-based publishing company, by 2050, the projected rise in osteoarthritis cases globally is expected to be 74.9% (ranging from 59.4% to 89.9%) for the knee, 48.6% (ranging from 35.9% to 67.1%) for the hand, 78.6% (ranging from 57.7% to 105.3%) for the hip, and 95.1% (ranging from 68.1% to 135.0%) for other osteoarthritis types. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Therefore, an increase in the prevalence of osteoarthritis is expected to drive the plasma therapy industry.Key Players In The Global Plasma Therapy Market
Major companies operating in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex Inc., Biotest AG, China Biologic Products Holdings Inc., DePuy Synthes Companies, CSL Limited, Grifols S.A., Octapharma AG, Terumo BCT Inc., Pfizer Inc., Kedrion Biopharma, ADMA Biologics Inc., SK Plasma Co. Ltd., Kamada Ltd., Fusion HealthCare, LFB Plasma, Baxter International Inc., Bayer AG, GC Biopharma Corp, Hualan Biological Engineering Inc., Japan Blood Products Organization, PlasmaCare Inc., ProMetic Life Sciences Inc., Sanquin, Shanghai RAAS Blood Products Co. Ltd., Canadian Plasma Resources, B Positive Plasma, Proesis Biologics Inc.Global Plasma Therapy Market Trends and Insights
Major companies operating in the plasma therapy market are introducing innovative products such as the ESG-410 to cater to the evolving needs and enhance treatment options. The ESG-410 is an Electrosurgical Generator designed to provide options and efficiencies in the treatment of NMIBC (non-muscle-invasive bladder cancer) and benign prostatic hyperplasia. For instance, in June 2023, Olympus Corporation, a Japan-based medical technology company launched the next-generation electrosurgical generator, ESG-410. This is used for treating bladder cancer and enlarged prostate. The ESG-410 features advanced design elements, such as enhanced capacitors, ensuring superior plasma stability during ignition. It boasts rapid ignition and optimized plasma stability, offering improvements over the ESG-400, especially when used with various loop sizes and oval buttons. The ESG-410 Electrosurgical Generator offers advanced treatment options for NMIBC and BPH by providing a range of resection loops, electrodes, and vaporization tools.What Are Latest Mergers And Acquisitions In The Plasma Therapy Market?
In October 2025, Accord Plasma B.V., a Netherlands-based provider of plasma-derived therapies, acquired Prothya Biosolutions B.V. for an undisclosed amount. With this acquisition, Accord Plasma B.V. aims to expand its global plasma therapy capabilities, enhance production efficiency, increase access to high-quality plasma-derived products, and strengthen its position in the biopharmaceutical market. Prothya Biosolutions B.V. is a US-based plasma collection and manufacturing company specializing in plasma-derived therapies.Regional Insights
North America was the largest region in the plasma therapy market in 2025. The Middle East is expected to be the fastest-growing region in the global plasma therapy market share during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Plasma Therapy Market?
The plasma therapy market includes revenues earned by entities by replacing missing or deficient proteins and developing better means of managing the disease. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Plasma Therapy Market Report 2026?
The plasma therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plasma therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Plasma Therapy Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $0.69 billion |
| Revenue Forecast In 2035 | $1.13 billion |
| Growth Rate | CAGR of 12.6% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Application, End-Users |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex Inc., Biotest AG, China Biologic Products Holdings Inc., DePuy Synthes Companies, CSL Limited, Grifols S.A., Octapharma AG, Terumo BCT Inc., Pfizer Inc., Kedrion Biopharma, ADMA Biologics Inc., SK Plasma Co. Ltd., Kamada Ltd., Fusion HealthCare, LFB Plasma, Baxter International Inc., Bayer AG, GC Biopharma Corp, Hualan Biological Engineering Inc., Japan Blood Products Organization, PlasmaCare Inc., ProMetic Life Sciences Inc., Sanquin, Shanghai RAAS Blood Products Co. Ltd., Canadian Plasma Resources, B Positive Plasma, Proesis Biologics Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
